Clinical Research Trials Archive – Closed Trials

This is our archive of closed clinical trials, which means that they are no longer accepting new participants or have been concluded. Once a research facility has chosen to close the study, it is sorted into the GPS archive by indication. If you are interested in enrolling in a clinical trial, then please browse our list of active clinical studies.

Zip code

Condition


Search Radius:25 Miles
  • 5
  • 10
  • 15
  • 20
  • 25
  • 30
  • 40
  • 50
  • 100
  • 500
  • All

We've found
25,125
archived clinical trials in
Diabetes

The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification
The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification
Status: Enrolling
Updated:  8/25/2017
Novo Nordisk Investigational Site
mi
from
San Antonio, TX
The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification
The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification
Status: Enrolling
Updated: 8/25/2017
Novo Nordisk Investigational Site
mi
from
San Antonio, TX
Click here to add this to my saved trials
The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification
The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification
Status: Enrolling
Updated:  8/25/2017
Novo Nordisk Investigational Site
mi
from
Sugar Land, TX
The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification
The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification
Status: Enrolling
Updated: 8/25/2017
Novo Nordisk Investigational Site
mi
from
Sugar Land, TX
Click here to add this to my saved trials
The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification
The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification
Status: Enrolling
Updated:  8/25/2017
Novo Nordisk Investigational Site
mi
from
Saint George, UT
The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification
The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification
Status: Enrolling
Updated: 8/25/2017
Novo Nordisk Investigational Site
mi
from
Saint George, UT
Click here to add this to my saved trials
The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification
The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification
Status: Enrolling
Updated:  8/25/2017
Novo Nordisk Investigational Site
mi
from
Salt Lake City, UT
The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification
The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification
Status: Enrolling
Updated: 8/25/2017
Novo Nordisk Investigational Site
mi
from
Salt Lake City, UT
Click here to add this to my saved trials
The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification
The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification
Status: Enrolling
Updated:  8/25/2017
Novo Nordisk Investigational Site
mi
from
Newport News, VA
The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification
The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification
Status: Enrolling
Updated: 8/25/2017
Novo Nordisk Investigational Site
mi
from
Newport News, VA
Click here to add this to my saved trials
The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification
The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification
Status: Enrolling
Updated:  8/25/2017
Novo Nordisk Investigational Site
mi
from
Spokane, WA
The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification
The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification
Status: Enrolling
Updated: 8/25/2017
Novo Nordisk Investigational Site
mi
from
Spokane, WA
Click here to add this to my saved trials
The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification
The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification
Status: Enrolling
Updated:  8/25/2017
Novo Nordisk Investigational Site
mi
from
Milwaukee, WI
The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification
The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification
Status: Enrolling
Updated: 8/25/2017
Novo Nordisk Investigational Site
mi
from
Milwaukee, WI
Click here to add this to my saved trials
The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification
The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification
Status: Enrolling
Updated:  8/25/2017
Novo Nordisk Investigational Site
mi
from
Delta,
The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification
The Effect of Insulin Degludec in Combination With Liraglutide and Metformin in Subjects With Type 2 Diabetes Qualifying for Treatment Intensification
Status: Enrolling
Updated: 8/25/2017
Novo Nordisk Investigational Site
mi
from
Delta,
Click here to add this to my saved trials
Metformin at the Cellular Level and Dosing for Diabetes Mellitus (DM)
Pilot Study of Metformin-induced CBP Phosphorylation at the Cellular Level and Corresponding Clinical Dose Response in Adults and Children
Status: Enrolling
Updated:  8/28/2017
Johns Hopkins University
mi
from
Baltimore, MD
Metformin at the Cellular Level and Dosing for Diabetes Mellitus (DM)
Pilot Study of Metformin-induced CBP Phosphorylation at the Cellular Level and Corresponding Clinical Dose Response in Adults and Children
Status: Enrolling
Updated: 8/28/2017
Johns Hopkins University
mi
from
Baltimore, MD
Click here to add this to my saved trials
Randomized Sitagliptin Withdrawal Study (MK-0431-845)
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of the Continuation of Sitagliptin Compared With the Withdrawal of Sitagliptin During Initiation and Titration of Insulin Glargine (LANTUS®) in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  8/29/2017
Clinical Research Facility
mi
from
Kingsport, TN
Randomized Sitagliptin Withdrawal Study (MK-0431-845)
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of the Continuation of Sitagliptin Compared With the Withdrawal of Sitagliptin During Initiation and Titration of Insulin Glargine (LANTUS®) in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 8/29/2017
Clinical Research Facility
mi
from
Kingsport, TN
Click here to add this to my saved trials
Randomized Sitagliptin Withdrawal Study (MK-0431-845)
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of the Continuation of Sitagliptin Compared With the Withdrawal of Sitagliptin During Initiation and Titration of Insulin Glargine (LANTUS®) in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  8/29/2017
Clinical Research Facility
mi
from
Richmond, VA
Randomized Sitagliptin Withdrawal Study (MK-0431-845)
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of the Continuation of Sitagliptin Compared With the Withdrawal of Sitagliptin During Initiation and Titration of Insulin Glargine (LANTUS®) in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 8/29/2017
Clinical Research Facility
mi
from
Richmond, VA
Click here to add this to my saved trials
Randomized Sitagliptin Withdrawal Study (MK-0431-845)
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of the Continuation of Sitagliptin Compared With the Withdrawal of Sitagliptin During Initiation and Titration of Insulin Glargine (LANTUS®) in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  8/29/2017
Clinical Research Facility
mi
from
Chandler, AZ
Randomized Sitagliptin Withdrawal Study (MK-0431-845)
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of the Continuation of Sitagliptin Compared With the Withdrawal of Sitagliptin During Initiation and Titration of Insulin Glargine (LANTUS®) in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 8/29/2017
Clinical Research Facility
mi
from
Chandler, AZ
Click here to add this to my saved trials
Randomized Sitagliptin Withdrawal Study (MK-0431-845)
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of the Continuation of Sitagliptin Compared With the Withdrawal of Sitagliptin During Initiation and Titration of Insulin Glargine (LANTUS®) in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  8/29/2017
Clinical Research Facility
mi
from
Louisville, KY
Randomized Sitagliptin Withdrawal Study (MK-0431-845)
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of the Continuation of Sitagliptin Compared With the Withdrawal of Sitagliptin During Initiation and Titration of Insulin Glargine (LANTUS®) in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 8/29/2017
Clinical Research Facility
mi
from
Louisville, KY
Click here to add this to my saved trials
Randomized Sitagliptin Withdrawal Study (MK-0431-845)
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of the Continuation of Sitagliptin Compared With the Withdrawal of Sitagliptin During Initiation and Titration of Insulin Glargine (LANTUS®) in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  8/29/2017
Clinical Research Facility
mi
from
Houston, TX
Randomized Sitagliptin Withdrawal Study (MK-0431-845)
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of the Continuation of Sitagliptin Compared With the Withdrawal of Sitagliptin During Initiation and Titration of Insulin Glargine (LANTUS®) in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 8/29/2017
Clinical Research Facility
mi
from
Houston, TX
Click here to add this to my saved trials
Randomized Sitagliptin Withdrawal Study (MK-0431-845)
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of the Continuation of Sitagliptin Compared With the Withdrawal of Sitagliptin During Initiation and Titration of Insulin Glargine (LANTUS®) in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  8/29/2017
Clinical Research Facility
mi
from
Chesapeake, VA
Randomized Sitagliptin Withdrawal Study (MK-0431-845)
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of the Continuation of Sitagliptin Compared With the Withdrawal of Sitagliptin During Initiation and Titration of Insulin Glargine (LANTUS®) in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 8/29/2017
Clinical Research Facility
mi
from
Chesapeake, VA
Click here to add this to my saved trials
Randomized Sitagliptin Withdrawal Study (MK-0431-845)
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of the Continuation of Sitagliptin Compared With the Withdrawal of Sitagliptin During Initiation and Titration of Insulin Glargine (LANTUS®) in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  8/29/2017
Clinical Research Facility
mi
from
Cooper City, FL
Randomized Sitagliptin Withdrawal Study (MK-0431-845)
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of the Continuation of Sitagliptin Compared With the Withdrawal of Sitagliptin During Initiation and Titration of Insulin Glargine (LANTUS®) in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 8/29/2017
Clinical Research Facility
mi
from
Cooper City, FL
Click here to add this to my saved trials
Randomized Sitagliptin Withdrawal Study (MK-0431-845)
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of the Continuation of Sitagliptin Compared With the Withdrawal of Sitagliptin During Initiation and Titration of Insulin Glargine (LANTUS®) in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  8/29/2017
Clinical Research Facility
mi
from
Miami, FL
Randomized Sitagliptin Withdrawal Study (MK-0431-845)
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of the Continuation of Sitagliptin Compared With the Withdrawal of Sitagliptin During Initiation and Titration of Insulin Glargine (LANTUS®) in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 8/29/2017
Clinical Research Facility
mi
from
Miami, FL
Click here to add this to my saved trials
Randomized Sitagliptin Withdrawal Study (MK-0431-845)
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of the Continuation of Sitagliptin Compared With the Withdrawal of Sitagliptin During Initiation and Titration of Insulin Glargine (LANTUS®) in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  8/29/2017
Clinical Research Facility
mi
from
Dallas, TX
Randomized Sitagliptin Withdrawal Study (MK-0431-845)
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of the Continuation of Sitagliptin Compared With the Withdrawal of Sitagliptin During Initiation and Titration of Insulin Glargine (LANTUS®) in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 8/29/2017
Clinical Research Facility
mi
from
Dallas, TX
Click here to add this to my saved trials
Randomized Sitagliptin Withdrawal Study (MK-0431-845)
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of the Continuation of Sitagliptin Compared With the Withdrawal of Sitagliptin During Initiation and Titration of Insulin Glargine (LANTUS®) in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  8/29/2017
Clinical Research Facility
mi
from
Plano, TX
Randomized Sitagliptin Withdrawal Study (MK-0431-845)
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of the Continuation of Sitagliptin Compared With the Withdrawal of Sitagliptin During Initiation and Titration of Insulin Glargine (LANTUS®) in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 8/29/2017
Clinical Research Facility
mi
from
Plano, TX
Click here to add this to my saved trials
Randomized Sitagliptin Withdrawal Study (MK-0431-845)
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of the Continuation of Sitagliptin Compared With the Withdrawal of Sitagliptin During Initiation and Titration of Insulin Glargine (LANTUS®) in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  8/29/2017
Clinical Research Facility
mi
from
Murray, UT
Randomized Sitagliptin Withdrawal Study (MK-0431-845)
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of the Continuation of Sitagliptin Compared With the Withdrawal of Sitagliptin During Initiation and Titration of Insulin Glargine (LANTUS®) in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 8/29/2017
Clinical Research Facility
mi
from
Murray, UT
Click here to add this to my saved trials
Randomized Sitagliptin Withdrawal Study (MK-0431-845)
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of the Continuation of Sitagliptin Compared With the Withdrawal of Sitagliptin During Initiation and Titration of Insulin Glargine (LANTUS®) in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  8/29/2017
Clinical Research Facility
mi
from
Northridge, CA
Randomized Sitagliptin Withdrawal Study (MK-0431-845)
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of the Continuation of Sitagliptin Compared With the Withdrawal of Sitagliptin During Initiation and Titration of Insulin Glargine (LANTUS®) in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 8/29/2017
Clinical Research Facility
mi
from
Northridge, CA
Click here to add this to my saved trials
Randomized Sitagliptin Withdrawal Study (MK-0431-845)
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of the Continuation of Sitagliptin Compared With the Withdrawal of Sitagliptin During Initiation and Titration of Insulin Glargine (LANTUS®) in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  8/29/2017
Clinical Research Facility
mi
from
Simi Valley, CA
Randomized Sitagliptin Withdrawal Study (MK-0431-845)
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of the Continuation of Sitagliptin Compared With the Withdrawal of Sitagliptin During Initiation and Titration of Insulin Glargine (LANTUS®) in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 8/29/2017
Clinical Research Facility
mi
from
Simi Valley, CA
Click here to add this to my saved trials
Randomized Sitagliptin Withdrawal Study (MK-0431-845)
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of the Continuation of Sitagliptin Compared With the Withdrawal of Sitagliptin During Initiation and Titration of Insulin Glargine (LANTUS®) in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  8/29/2017
Clinical Research Facility
mi
from
Hopewell Junction, NY
Randomized Sitagliptin Withdrawal Study (MK-0431-845)
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of the Continuation of Sitagliptin Compared With the Withdrawal of Sitagliptin During Initiation and Titration of Insulin Glargine (LANTUS®) in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 8/29/2017
Clinical Research Facility
mi
from
Hopewell Junction, NY
Click here to add this to my saved trials
Randomized Sitagliptin Withdrawal Study (MK-0431-845)
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of the Continuation of Sitagliptin Compared With the Withdrawal of Sitagliptin During Initiation and Titration of Insulin Glargine (LANTUS®) in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  8/29/2017
Clinical Research Facility
mi
from
Bellevue, WA
Randomized Sitagliptin Withdrawal Study (MK-0431-845)
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of the Continuation of Sitagliptin Compared With the Withdrawal of Sitagliptin During Initiation and Titration of Insulin Glargine (LANTUS®) in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 8/29/2017
Clinical Research Facility
mi
from
Bellevue, WA
Click here to add this to my saved trials
Randomized Sitagliptin Withdrawal Study (MK-0431-845)
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of the Continuation of Sitagliptin Compared With the Withdrawal of Sitagliptin During Initiation and Titration of Insulin Glargine (LANTUS®) in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  8/29/2017
Clinical Research Facility
mi
from
San Antonio, TX
Randomized Sitagliptin Withdrawal Study (MK-0431-845)
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of the Continuation of Sitagliptin Compared With the Withdrawal of Sitagliptin During Initiation and Titration of Insulin Glargine (LANTUS®) in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 8/29/2017
Clinical Research Facility
mi
from
San Antonio, TX
Click here to add this to my saved trials
Randomized Sitagliptin Withdrawal Study (MK-0431-845)
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of the Continuation of Sitagliptin Compared With the Withdrawal of Sitagliptin During Initiation and Titration of Insulin Glargine (LANTUS®) in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  8/29/2017
Clinical Research Facility
mi
from
New Port Richey, FL
Randomized Sitagliptin Withdrawal Study (MK-0431-845)
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of the Continuation of Sitagliptin Compared With the Withdrawal of Sitagliptin During Initiation and Titration of Insulin Glargine (LANTUS®) in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 8/29/2017
Clinical Research Facility
mi
from
New Port Richey, FL
Click here to add this to my saved trials
Randomized Sitagliptin Withdrawal Study (MK-0431-845)
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of the Continuation of Sitagliptin Compared With the Withdrawal of Sitagliptin During Initiation and Titration of Insulin Glargine (LANTUS®) in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  8/29/2017
Clinical Research Facility
mi
from
Corvallis, OR
Randomized Sitagliptin Withdrawal Study (MK-0431-845)
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of the Continuation of Sitagliptin Compared With the Withdrawal of Sitagliptin During Initiation and Titration of Insulin Glargine (LANTUS®) in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 8/29/2017
Clinical Research Facility
mi
from
Corvallis, OR
Click here to add this to my saved trials
Randomized Sitagliptin Withdrawal Study (MK-0431-845)
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of the Continuation of Sitagliptin Compared With the Withdrawal of Sitagliptin During Initiation and Titration of Insulin Glargine (LANTUS®) in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  8/29/2017
Clinical Research Facility
mi
from
Birmingham, AL
Randomized Sitagliptin Withdrawal Study (MK-0431-845)
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of the Continuation of Sitagliptin Compared With the Withdrawal of Sitagliptin During Initiation and Titration of Insulin Glargine (LANTUS®) in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 8/29/2017
Clinical Research Facility
mi
from
Birmingham, AL
Click here to add this to my saved trials
Randomized Sitagliptin Withdrawal Study (MK-0431-845)
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of the Continuation of Sitagliptin Compared With the Withdrawal of Sitagliptin During Initiation and Titration of Insulin Glargine (LANTUS®) in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  8/29/2017
Clinical Research Facility
mi
from
New Windsor, NY
Randomized Sitagliptin Withdrawal Study (MK-0431-845)
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of the Continuation of Sitagliptin Compared With the Withdrawal of Sitagliptin During Initiation and Titration of Insulin Glargine (LANTUS®) in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 8/29/2017
Clinical Research Facility
mi
from
New Windsor, NY
Click here to add this to my saved trials
Randomized Sitagliptin Withdrawal Study (MK-0431-845)
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of the Continuation of Sitagliptin Compared With the Withdrawal of Sitagliptin During Initiation and Titration of Insulin Glargine (LANTUS®) in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  8/29/2017
Clinical Research Facility
mi
from
Cincinnati, OH
Randomized Sitagliptin Withdrawal Study (MK-0431-845)
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of the Continuation of Sitagliptin Compared With the Withdrawal of Sitagliptin During Initiation and Titration of Insulin Glargine (LANTUS®) in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 8/29/2017
Clinical Research Facility
mi
from
Cincinnati, OH
Click here to add this to my saved trials
Randomized Sitagliptin Withdrawal Study (MK-0431-845)
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of the Continuation of Sitagliptin Compared With the Withdrawal of Sitagliptin During Initiation and Titration of Insulin Glargine (LANTUS®) in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  8/29/2017
Clinical Research Facility
mi
from
Roseville, CA
Randomized Sitagliptin Withdrawal Study (MK-0431-845)
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of the Continuation of Sitagliptin Compared With the Withdrawal of Sitagliptin During Initiation and Titration of Insulin Glargine (LANTUS®) in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 8/29/2017
Clinical Research Facility
mi
from
Roseville, CA
Click here to add this to my saved trials
Randomized Sitagliptin Withdrawal Study (MK-0431-845)
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of the Continuation of Sitagliptin Compared With the Withdrawal of Sitagliptin During Initiation and Titration of Insulin Glargine (LANTUS®) in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  8/29/2017
Clinical Research Facility
mi
from
New Orleans, LA
Randomized Sitagliptin Withdrawal Study (MK-0431-845)
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of the Continuation of Sitagliptin Compared With the Withdrawal of Sitagliptin During Initiation and Titration of Insulin Glargine (LANTUS®) in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 8/29/2017
Clinical Research Facility
mi
from
New Orleans, LA
Click here to add this to my saved trials
Randomized Sitagliptin Withdrawal Study (MK-0431-845)
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of the Continuation of Sitagliptin Compared With the Withdrawal of Sitagliptin During Initiation and Titration of Insulin Glargine (LANTUS®) in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  8/29/2017
Clinical Research Facility
mi
from
Cary, NC
Randomized Sitagliptin Withdrawal Study (MK-0431-845)
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of the Continuation of Sitagliptin Compared With the Withdrawal of Sitagliptin During Initiation and Titration of Insulin Glargine (LANTUS®) in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 8/29/2017
Clinical Research Facility
mi
from
Cary, NC
Click here to add this to my saved trials
Randomized Sitagliptin Withdrawal Study (MK-0431-845)
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of the Continuation of Sitagliptin Compared With the Withdrawal of Sitagliptin During Initiation and Titration of Insulin Glargine (LANTUS®) in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  8/29/2017
Clinical Research Facility
mi
from
Fargo, ND
Randomized Sitagliptin Withdrawal Study (MK-0431-845)
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of the Continuation of Sitagliptin Compared With the Withdrawal of Sitagliptin During Initiation and Titration of Insulin Glargine (LANTUS®) in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 8/29/2017
Clinical Research Facility
mi
from
Fargo, ND
Click here to add this to my saved trials
Randomized Sitagliptin Withdrawal Study (MK-0431-845)
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of the Continuation of Sitagliptin Compared With the Withdrawal of Sitagliptin During Initiation and Titration of Insulin Glargine (LANTUS®) in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  8/29/2017
Merck Sharp & Dohme (Argentina) Inc.
mi
from
Buenos Aires,
Randomized Sitagliptin Withdrawal Study (MK-0431-845)
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of the Continuation of Sitagliptin Compared With the Withdrawal of Sitagliptin During Initiation and Titration of Insulin Glargine (LANTUS®) in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 8/29/2017
Merck Sharp & Dohme (Argentina) Inc.
mi
from
Buenos Aires,
Click here to add this to my saved trials
Randomized Sitagliptin Withdrawal Study (MK-0431-845)
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of the Continuation of Sitagliptin Compared With the Withdrawal of Sitagliptin During Initiation and Titration of Insulin Glargine (LANTUS®) in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  8/29/2017
Clinical Research Facility
mi
from
Philadelphia, PA
Randomized Sitagliptin Withdrawal Study (MK-0431-845)
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of the Continuation of Sitagliptin Compared With the Withdrawal of Sitagliptin During Initiation and Titration of Insulin Glargine (LANTUS®) in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 8/29/2017
Clinical Research Facility
mi
from
Philadelphia, PA
Click here to add this to my saved trials
Randomized Sitagliptin Withdrawal Study (MK-0431-845)
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of the Continuation of Sitagliptin Compared With the Withdrawal of Sitagliptin During Initiation and Titration of Insulin Glargine (LANTUS®) in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated:  8/29/2017
Clinical Research Facility
mi
from
Greer, SC
Randomized Sitagliptin Withdrawal Study (MK-0431-845)
A Phase III, Multicenter, Randomized, Double-Blind, Placebo-Controlled Clinical Trial to Study the Efficacy and Safety of the Continuation of Sitagliptin Compared With the Withdrawal of Sitagliptin During Initiation and Titration of Insulin Glargine (LANTUS®) in Subjects With Type 2 Diabetes Mellitus
Status: Enrolling
Updated: 8/29/2017
Clinical Research Facility
mi
from
Greer, SC
Click here to add this to my saved trials
In Clinic Evaluation of the PLGM Feature
In-Clinic Evaluation of the Predictive Low Glucose Management (PLGM) System in Adult and Pediatric Insulin Requiring Patients With Diabetes Using the Enlite 3 Sensor
Status: Enrolling
Updated:  8/30/2017
AMCR Institute, Inc
mi
from
Escondido, CA
In Clinic Evaluation of the PLGM Feature
In-Clinic Evaluation of the Predictive Low Glucose Management (PLGM) System in Adult and Pediatric Insulin Requiring Patients With Diabetes Using the Enlite 3 Sensor
Status: Enrolling
Updated: 8/30/2017
AMCR Institute, Inc
mi
from
Escondido, CA
Click here to add this to my saved trials
In Clinic Evaluation of the PLGM Feature
In-Clinic Evaluation of the Predictive Low Glucose Management (PLGM) System in Adult and Pediatric Insulin Requiring Patients With Diabetes Using the Enlite 3 Sensor
Status: Enrolling
Updated:  8/30/2017
Stanford University Department of Pediatric Endocrinology
mi
from
Stanford, CA
In Clinic Evaluation of the PLGM Feature
In-Clinic Evaluation of the Predictive Low Glucose Management (PLGM) System in Adult and Pediatric Insulin Requiring Patients With Diabetes Using the Enlite 3 Sensor
Status: Enrolling
Updated: 8/30/2017
Stanford University Department of Pediatric Endocrinology
mi
from
Stanford, CA
Click here to add this to my saved trials
In Clinic Evaluation of the PLGM Feature
In-Clinic Evaluation of the Predictive Low Glucose Management (PLGM) System in Adult and Pediatric Insulin Requiring Patients With Diabetes Using the Enlite 3 Sensor
Status: Enrolling
Updated:  8/30/2017
Diablo Clinical Research Inc
mi
from
Walnut creek, CA
In Clinic Evaluation of the PLGM Feature
In-Clinic Evaluation of the Predictive Low Glucose Management (PLGM) System in Adult and Pediatric Insulin Requiring Patients With Diabetes Using the Enlite 3 Sensor
Status: Enrolling
Updated: 8/30/2017
Diablo Clinical Research Inc
mi
from
Walnut creek, CA
Click here to add this to my saved trials
In Clinic Evaluation of the PLGM Feature
In-Clinic Evaluation of the Predictive Low Glucose Management (PLGM) System in Adult and Pediatric Insulin Requiring Patients With Diabetes Using the Enlite 3 Sensor
Status: Enrolling
Updated:  8/30/2017
Barbara Davis Center for Childhood Diabetes
mi
from
Denver, CO
In Clinic Evaluation of the PLGM Feature
In-Clinic Evaluation of the Predictive Low Glucose Management (PLGM) System in Adult and Pediatric Insulin Requiring Patients With Diabetes Using the Enlite 3 Sensor
Status: Enrolling
Updated: 8/30/2017
Barbara Davis Center for Childhood Diabetes
mi
from
Denver, CO
Click here to add this to my saved trials
In Clinic Evaluation of the PLGM Feature
In-Clinic Evaluation of the Predictive Low Glucose Management (PLGM) System in Adult and Pediatric Insulin Requiring Patients With Diabetes Using the Enlite 3 Sensor
Status: Enrolling
Updated:  8/30/2017
Yale University Diabetes Research Program
mi
from
New Haven, CT
In Clinic Evaluation of the PLGM Feature
In-Clinic Evaluation of the Predictive Low Glucose Management (PLGM) System in Adult and Pediatric Insulin Requiring Patients With Diabetes Using the Enlite 3 Sensor
Status: Enrolling
Updated: 8/30/2017
Yale University Diabetes Research Program
mi
from
New Haven, CT
Click here to add this to my saved trials
In Clinic Evaluation of the PLGM Feature
In-Clinic Evaluation of the Predictive Low Glucose Management (PLGM) System in Adult and Pediatric Insulin Requiring Patients With Diabetes Using the Enlite 3 Sensor
Status: Enrolling
Updated:  8/30/2017
Atlanta Diabetes Associates
mi
from
Atlanta, GA
In Clinic Evaluation of the PLGM Feature
In-Clinic Evaluation of the Predictive Low Glucose Management (PLGM) System in Adult and Pediatric Insulin Requiring Patients With Diabetes Using the Enlite 3 Sensor
Status: Enrolling
Updated: 8/30/2017
Atlanta Diabetes Associates
mi
from
Atlanta, GA
Click here to add this to my saved trials
In Clinic Evaluation of the PLGM Feature
In-Clinic Evaluation of the Predictive Low Glucose Management (PLGM) System in Adult and Pediatric Insulin Requiring Patients With Diabetes Using the Enlite 3 Sensor
Status: Enrolling
Updated:  8/30/2017
University of Virgina
mi
from
Charlottesville, VA
In Clinic Evaluation of the PLGM Feature
In-Clinic Evaluation of the Predictive Low Glucose Management (PLGM) System in Adult and Pediatric Insulin Requiring Patients With Diabetes Using the Enlite 3 Sensor
Status: Enrolling
Updated: 8/30/2017
University of Virgina
mi
from
Charlottesville, VA
Click here to add this to my saved trials
In Clinic Evaluation of the PLGM Feature
In-Clinic Evaluation of the Predictive Low Glucose Management (PLGM) System in Adult and Pediatric Insulin Requiring Patients With Diabetes Using the Enlite 3 Sensor
Status: Enrolling
Updated:  8/30/2017
Rainier Clinical Research
mi
from
Renton, WA
In Clinic Evaluation of the PLGM Feature
In-Clinic Evaluation of the Predictive Low Glucose Management (PLGM) System in Adult and Pediatric Insulin Requiring Patients With Diabetes Using the Enlite 3 Sensor
Status: Enrolling
Updated: 8/30/2017
Rainier Clinical Research
mi
from
Renton, WA
Click here to add this to my saved trials
Medtronic Treat to Range (TTR) Closed-Loop Control
Medtronic Treat to Range (TTR) Closed-Loop Control: Tuning a Treat-to-Range Controller for the Effects of High and Low Glycemic Index Meals
Status: Enrolling
Updated:  8/31/2017
Stanford University and Stanford Hospital & Clinics
mi
from
Stanford, CA
Medtronic Treat to Range (TTR) Closed-Loop Control
Medtronic Treat to Range (TTR) Closed-Loop Control: Tuning a Treat-to-Range Controller for the Effects of High and Low Glycemic Index Meals
Status: Enrolling
Updated: 8/31/2017
Stanford University and Stanford Hospital & Clinics
mi
from
Stanford, CA
Click here to add this to my saved trials
Metformin's Effect on Glucagon-induced Glucose Production and Protein Metabolism.
Metformin's Effect on Glucagon-induced Endogenous Glucose Production, Protein Metabolism and Resting Energy Expenditure in Insulin Resistant Individuals.
Status: Enrolling
Updated:  8/31/2017
Mayo Clinic Rochester
mi
from
Rochester, MN
Metformin's Effect on Glucagon-induced Glucose Production and Protein Metabolism.
Metformin's Effect on Glucagon-induced Endogenous Glucose Production, Protein Metabolism and Resting Energy Expenditure in Insulin Resistant Individuals.
Status: Enrolling
Updated: 8/31/2017
Mayo Clinic Rochester
mi
from
Rochester, MN
Click here to add this to my saved trials
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated:  9/5/2017
GSK Investigational Site
mi
from
Birmingham, AL
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated: 9/5/2017
GSK Investigational Site
mi
from
Birmingham, AL
Click here to add this to my saved trials
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated:  9/5/2017
GSK Investigational Site
mi
from
Little Rock, AR
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated: 9/5/2017
GSK Investigational Site
mi
from
Little Rock, AR
Click here to add this to my saved trials
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated:  9/5/2017
GSK Investigational Site
mi
from
Costa Mesa, CA
Trial of Otelixizumab for Adults With Newly Diagnosed Type 1 Diabetes Mellitus (Autoimmune): DEFEND-1
Durable-Response Therapy Evaluation For Early or New-Onset Type 1 Diabetes - DEFEND
Status: Enrolling
Updated: 9/5/2017
GSK Investigational Site
mi
from
Costa Mesa, CA
Click here to add this to my saved trials